Arcutis Biotherapeutics (NASDAQ:ARQT) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Arcutis Biotherapeutics (NASDAQ:ARQT – Free Report) in a research note published on Wednesday,Benzinga reports. They currently have a $20.00 price objective on the stock. Several other research firms have also weighed in on ARQT. Jefferies Financial Group upped their price objective on Arcutis Biotherapeutics […]